Data on Viamet’s VT-1161 for Treatment of RVVC to be Presented at IDSOG Annual Meeting
Viamet Pharmaceuticals, Inc. today announced that results from the Company’s REVIVE study, a Phase 2b clinical trial of VT-1161 in the treatment of patients with recurrent vulvovaginal candidiasis (RVVC), will be highlighted in an oral presentation at the upcoming Infectious Diseases Society for Obstetrics and Gynecology (IDSOG) Annual Meeting being held August 10 to 12 in Park City, Utah. The presentation will be given by Jack Sobel, M.D., one of the world’s foremost authorities on vaginal yeast infections, and a clinical investigator in the REVIVE clinical trial. VT-1161, a novel inhibitor of fungal CYP51, recently completed a Phase 2b trial for the treatment of RVVC, a common condition for which there are currently no approved therapies in the United States. It is estimated that RVVC afflicts 5 to 8 percent of women of child-bearing age, and can be a source of significant concern and discomfort leading to a negative impact on quality of life.